Image source: Getty Images.
Tesaro (NASDAQ: TSRO) saw its shares increase 108% on Wednesday after announcing that its cancer drug, niraparib, extended progression-free survival — a measure of how long it takes a tumor to start growing again — in patients with ovarian cancer.